Ironwood Pharmaceuti (IRWD) Stock Price, Quote & News

Company Profile

Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA name...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 617 621 7722

Fax: 617 494 0480

Website: ironwoodpharma.com

Address:

100 Summer Street, Suite 2300, Boston, United States

BonprixUltimateGuardians May. 13 at 8:51 PM

$CAG $CLF $AIFF $SOBR $IRWD business

0 · Reply

Marks6972 May. 13 at 8:19 PM

$IRWD

0 · Reply

Bio_Invest101 May. 13 at 7:27 PM

$IRWD Blackrock added over 1/2 million shares and its holding is about 13.4 million shares total at averaged price $12 I hope retails not over thinking too much of today’s CFO resignation event and got taken advantage by funds. That 1st Q Linzess results were confirmed and verified by our partner in ABBV which we most certainly could trust more than Tom Strong hold https://hedgefollow.com/stocks/IRWD

0 · Reply

revuelto May. 13 at 7:24 PM

$IRWD I said months back that I would sell out of my position here but I kept holding because the mc looked way too sus for what they actually have…today’s news is sus too…just sus sus sus all around….never get tired of this space 😀

0 · Reply

StockTwitsGhost May. 13 at 6:51 PM

$IRWD The clearest signal is behavioral: a long tenured CFO giving roughly one week’s notice during a strategic process usually means he either already has economic protection and visibility into the likely endgame or no longer wants to remain attached to the outcome. The proxy’s parachute provisions make the former materially more plausible.

0 · Reply

StockTwitsGhost May. 13 at 6:50 PM

$IRWD If I had to synthesize today’s incompetence signals into one cohesive view, I’d say the resignation itself was abnormal, but the surrounding structure does not appear random. The disclosure timing may have been technically compliant, yet strategically tone deaf and the broader pattern points more toward transaction related disruption than outright corporate crisis, though neither can be ruled out. What pulls me away from the catastrophic interpretation is the absence of disclosed accounting or reporting disputes, the active Goldman strategic review backdrop, the existence of CIC protections, the use of interim finance leadership instead of an urgent outside replacement and the fact the CFO still participated in the earnings call immediately beforehand. If an accounting or governance blowup were imminent, putting the CFO front and center one day before the resignation surfaced would have been idiotically risky.

0 · Reply

ASKING7 May. 13 at 6:38 PM

$IRWD as CFO already signed all the legal docs for the Q1, so the number should be right. But meanwhile assigned Corporate Controller and Chief Accounting Officer will serve as the Company’s interim CFO seems like a last "Integration Phase". I will be not surprised if buyer wants to use the CFO news to shake out the last time and lower the VWAP, so the cheap BO offer can be consider as a "Good Deal" to justify the "Best interest for the shareholders". Gonna wait and see if any more SEC file coming out, maybe I am too optimistic, but this show can also get as dark as it could.

2 · Reply

StockTwitsGhost May. 13 at 6:11 PM

$IRWD I hope IRWD C-Suite is reading this. Legally compliant is not the same thing as governance-best-practice. By delaying until the edge of the filing window, you unintentionally increased suspicion. You amplified investor sensitivity and as others have stated, I agree that you aren’t qualified to run a lemonade stand. In a vacuum, a three-business day delay is fine but we aren’t sitting inside a Dyson. Just my opinion but you are truly incompetent. If this offends you then the label fits. 🫳🏽🎤

1 · Reply

Bio_Invest101 May. 13 at 4:59 PM

$IRWD On May 13, 2026 - Acadian Asset Management Llc filed a 13F-HR form disclosing ownership of 6,577,272 shares of Ironwood Pharmaceuticals, Inc. (US:IRWD) valued at $23,086,225 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 10, 2026 disclosing 6,457,817 shares of Ironwood Pharmaceuticals, Inc.. This represents a change in shares of 1.85% during the quarter. The current value of the position is $26,901,042 USD.

0 · Reply

TeeMan123 May. 13 at 2:59 PM

$IRWD after everything this mgmt team and board has done, why the fk can’t they have the brains to at least comment on the guide with such an announcement.

1 · Reply

Ironwood Pharmaceuticals Earnings Call Transcript: Q1 2026

May 7, 2026, 7:05 AM EDT - 6 days ago

Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance

2026-05-04T11:11:53.000Z - 9 days ago

Ironwood presents new findings at DDW 2026 from survey treatment of SBS

May 4, 2026, 7:05 AM EDT - 9 days ago

Ironwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS)

Apr 30, 2026, 4:05 PM EDT - 13 days ago

Ironwood Pharmaceuticals to Host First Quarter 2026 Investor Update Call

2026-04-23T11:25:41.000Z - 20 days ago

Ironwood to present data from Landmark survey on SBS

Apr 23, 2026, 7:05 AM EDT - 20 days ago

Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026

SBS

Mar 11, 2026, 4:00 PM EDT - 2 months ago

Ironwood Pharmaceuticals Transcript: The Citizens Life Sciences Conference 2026

Mar 4, 2026, 4:05 PM EST - 2 months ago

Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference

2026-02-26T11:08:56.000Z - 2 months ago

Ironwood price target raised to $10 from $8 at Citizens

Feb 25, 2026, 8:30 AM EST - 2 months ago

Ironwood Pharmaceuticals Earnings Call Transcript: Q4 2025

Feb 25, 2026, 7:05 AM EST - 2 months ago

Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 Outlook

Feb 18, 2026, 4:21 PM EST - 3 months ago

Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Investor Update Call

2026-01-05T12:37:19.000Z - 4 months ago

Craig-Hallum upgrades Ironwood to Buy following 2026 guidance

2026-01-05T12:20:08.000Z - 4 months ago

Ironwood upgraded to Buy from Hold at Craig-Hallum

2026-01-05T10:15:33.000Z - 4 months ago

Ironwood upgraded to Outperform from Market Perform at Citizens

2026-01-04T23:25:05.000Z - 4 months ago

Ironwood price target raised to $5 from $3 at Wells Fargo

2026-01-02T17:29:08.000Z - 4 months ago

Why Did Ironwood Pharma Stock (IRWD) Jump 30% Today?

PFE

Jan 2, 2026, 7:05 AM EST - 4 months ago

Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance

2025-11-26T15:10:47.000Z - 6 months ago

Ironwood price target raised to $3.80 from $1.70 at Craig-Hallum

Nov 10, 2025, 7:05 AM EST - 6 months ago

Ironwood Pharmaceuticals Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial Guidance

Oct 24, 2025, 8:10 AM EDT - 7 months ago

Ironwood Stair & Rail Inc. Recognised With 2025 Consumer Choice Award for Stairs and Railings in Southern Alberta

Aug 7, 2025, 7:05 AM EDT - 9 months ago

Ironwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial Guidance

May 7, 2025, 12:00 PM EDT - 1 year ago

Ironwood Pharmaceuticals Transcript: The Citizens JMP Life Sciences Conference 2025

May 7, 2025, 7:05 AM EDT - 1 year ago

Ironwood Pharmaceuticals Reports First Quarter 2025 Results

Apr 25, 2025, 7:05 AM EDT - 1 year ago

Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance

Apr 22, 2025, 4:05 PM EDT - 1 year ago

Ironwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week® 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support

Apr 14, 2025, 7:00 AM EDT - 1 year ago

Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide

Mar 27, 2025, 4:05 PM EDT - 1 year ago

Ironwood Pharmaceuticals Announces Receipt of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K Filing

Mar 25, 2025, 8:30 AM EDT - 1 year ago

Industry Veteran Launches Ironwood III With Substantial Equity Commitment From Kayne Anderson Energy Infrastructure Fund

Feb 27, 2025, 8:30 AM EST - 1 year ago

Ironwood Pharmaceuticals Earnings Call Transcript: Q4 2024

Feb 27, 2025, 7:00 AM EST - 1 year ago

Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial Guidance

Feb 20, 2025, 4:00 PM EST - 1 year ago

Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Investor Update Call

Jan 29, 2025, 4:30 PM EST - 1 year ago

Ironwood Pharmaceuticals Transcript: Status Update

Jan 29, 2025, 4:05 PM EST - 1 year ago

Ironwood Pharmaceuticals Initiates Apraglutide NDA Submission, Highlights Compelling New Data and Updates Corporate Structure to Position for the Future

Jan 17, 2025, 8:07 AM EST - 1 year ago

Ozempic is in the next round of Medicare drug price negotiations. See the full list of 15 medications

Dec 4, 2024, 12:30 PM EST - 1 year ago

Ironwood Pharmaceuticals Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 26, 2024, 4:01 PM EST - 1 year ago

Ironwood Pharmaceuticals to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 20, 2024, 2:30 AM EST - 1 year ago

Ironwood Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2024

Nov 13, 2024, 4:01 PM EST - 1 year ago

Ironwood Pharmaceuticals to Participate in the Jefferies London Healthcare Conference

Nov 7, 2024, 8:30 AM EST - 1 year ago

Ironwood Pharmaceuticals Earnings Call Transcript: Q3 2024

Nov 7, 2024, 7:00 AM EST - 1 year ago

Ironwood Pharmaceuticals Reports Third Quarter 2024 Results

Oct 28, 2024, 7:00 AM EDT - 1 year ago

Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics and Disease Characteristics in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF), According to New STARS Phase III Data from Ironwood at ACG 2024

Oct 24, 2024, 4:00 PM EDT - 1 year ago

Ironwood Pharmaceuticals to Host Third Quarter 2024 Investor Update Call

Sep 5, 2024, 2:15 PM EDT - 1 year ago

Ironwood Pharmaceuticals Transcript: 2024 Wells Fargo Healthcare Conference

Aug 29, 2024, 4:01 PM EDT - 1 year ago

Ironwood Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference

Aug 8, 2024, 8:30 AM EDT - 1 year ago

Ironwood Pharmaceuticals Earnings Call Transcript: Q2 2024

Aug 8, 2024, 7:00 AM EDT - 1 year ago

Ironwood Pharmaceuticals Reports Second Quarter 2024 Results

Jul 25, 2024, 4:00 PM EDT - 1 year ago

Ironwood Pharmaceuticals to Host Second Quarter 2024 Investor Update Call

Jun 18, 2024, 9:00 AM EDT - 2 years ago

Ironwood Pharmaceuticals Transcript: AGM 2024

Jun 6, 2024, 9:00 AM EDT - 2 years ago

Ironwood Pharmaceuticals Transcript: Jefferies 2024 Global Healthcare Conference

May 30, 2024, 4:01 PM EDT - 2 years ago

Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference

BonprixUltimateGuardians May. 13 at 8:51 PM

$CAG $CLF $AIFF $SOBR $IRWD business

0 · Reply

Marks6972 May. 13 at 8:19 PM

$IRWD

0 · Reply

Bio_Invest101 May. 13 at 7:27 PM

0 · Reply

revuelto May. 13 at 7:24 PM

0 · Reply

StockTwitsGhost May. 13 at 6:51 PM

0 · Reply

StockTwitsGhost May. 13 at 6:50 PM

0 · Reply

ASKING7 May. 13 at 6:38 PM

2 · Reply

StockTwitsGhost May. 13 at 6:11 PM

1 · Reply

Bio_Invest101 May. 13 at 4:59 PM

0 · Reply

TeeMan123 May. 13 at 2:59 PM

$IRWD after everything this mgmt team and board has done, why the fk can’t they have the brains to at least comment on the guide with such an announcement.

1 · Reply

Nibbler May. 13 at 2:58 PM

$IRWD

0 · Reply

StockTwitsGhost May. 13 at 2:51 PM

$IRWD The 2026 Proxy Statement contains an explicit Golden Parachute provision in the section titled "Potential Payments Upon Termination or Change in Control." This legal language mandates that if a "Change in Control" (buyout) occurs, the company must provide executive officers, specifically including CFO Martini, a cash payout of 1.5x to 2x their base salary and bonus, along with 100% accelerated vesting of all equity. Crucially, management can carve out exceptions for a departing executive through a "tail" provision, which ensures that even if he leaves shortly before a deal is signed, he still receives the full multi-million dollar payout instead of the "forfeiture" currently shown on paper.

1 · Reply

Solaf May. 13 at 2:51 PM

$IRWD I would say what is dead may never die but this company killed us a dozen of times last 2 years.

0 · Reply

Bio_Invest101 May. 13 at 2:50 PM

$IRWD Small but very high percentage and this company never owned more than 100 K shares since 2013 until now Mackenzie Financial Corp reports 4,751.30% increase in ownership of IRWD / Ironwood Pharmaceuticals, Inc. On May 13, 2026 - Mackenzie Financial Corp filed a 13F-HR form disclosing ownership of 560,034 shares of Ironwood Pharmaceuticals, Inc. (US:IRWD) valued at $1,965,719 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 18, 2026 disclosing 11,544 shares of Ironwood Pharmaceuticals, Inc.. This represents a change in shares of 4,751.30% during the quarter. The current value of the position is $2,290,539 USD.

0 · Reply

Bio_Invest101 May. 13 at 2:41 PM

$IRWD so at least for the past 4 weeks the SI reached record highs with longest DTC over 10 days. They knew The CFO was leaving so they’re not concerned even the 1st Q ER results were very good and full yr guides honored. Top executives leaving is normal and there’re so many ways to handle this event and news better but Tom choses to act irresponsibly knowing the news will hurt the SP but why ? Do they all want a lower VWAP to get the deal done?

0 · Reply

revuelto May. 13 at 2:23 PM

$IRWD had a chat with Greg last year…seemed like a good guy….I can only hope this is just house cleaning..sus sus sus

0 · Reply

Solaf May. 13 at 2:02 PM

$IRWD CFO resigned?

2 · Reply

TeeMan123 May. 13 at 1:55 PM

$IRWD these fking morons.. let the ceo resign but reaffirm guidance, everyone thinks these morons are miss managing the guide again

0 · Reply

Bio_Invest101 May. 13 at 12:29 PM

$IRWD Young CFO left “not due to Financial reports related issues or disagreement” … but maybe with Tom and BoD not executing a sell the company decision?? Btw he left without his free RSU grants next month! Interesting https://d18rn0p25nwr6d.cloudfront.net/CIK-0001446847/763b0b1b-54db-424f-bb56-c7a1e8aa93e0.pdf

1 · Reply

discussionbo7 May. 12 at 9:58 PM

$MRNA $SLS $TEM $IRWD health sector is coming

0 · Reply

MalekJ May. 11 at 11:34 PM

$IRWD Everyone serves their own agenda.

0 · Reply

StockTwitsGhost May. 11 at 10:52 PM

$IRWD You sounds more like a person playing a character of the "humble observer", while clearly possessing the vocabulary and mechanical understanding of a professional fund manager or a high-net-worth institutional trader.

1 · Reply

Market Cap	679.95M
Revenue (ttm)	296.15M
Net Income (ttm)	24.02M
EPS (ttm)	N/A
PE Ratio	6.92
Forward PE	4.80
Profit Margin	8.11%
Debt to Equity Ratio	-2.69

Volume	4,407,800
Avg Vol	2,492,668
Day's Range	N/A - N/A
Shares Out	163.06M
Stochastic %K	17%
Beta	0.29
Analysts	Sell
Price Target	$6.10